Smad4 is a tumor suppressor that is inactivated in about 50% of pancreatic carcinomas. Mutations in this gene have also been found with variable, yet much lower frequency in other tumor types and were absent from a large number of samples from patients with hematological malignancies. Smad2 shows considerable sequence similarity with Smad4 and cooperates with it in the growth inhibitory TGF-␤ pathway. Smad2 mutations have been found in a fraction of colon carcinomas and have been shown to impair the function of the corresponding proteins. However, only a few other tumor types have been screened for Smad2 mutations so far. Therefore, we analyzed 50 primary tumor samples from patients with acute lymphoid or myeloid leukemia (ALL or AML) and five cell lines of hematopoietic origin for alterations in the Smad2 gene. None of the specimens tested carried mutations in the conserved MH1 or MH2 domains of Smad2.
Introduction
The recently isolated Smad genes constitute an evolutionarily conserved gene family. In humans, they are presumed to play a role in tumorigenesis for two reasons: Smad2 and Smad4 act in the growth inhibitory TGF-␤ pathway;
1,2 and Smad4 (originally named DPC4, for deleted in pancreatic cancer 4) has been cloned as the gene affected by homozygous deletions of chromosome region 18q21.1 in 30% of pancreatic cancers. 3 TGF-␤ potently inhibits the proliferation of many cell types, including cells of epithelial and hematopoietic origin. 4, 5 Increased production of TGF-␤ by malignant cells 6 as well as resistance of tumor cells to TGF-␤ 7, 8 are commonly observed in neoplastic diseases and seem to contribute to their progression. In hematological malignancies, TGF-␤ overproduction plays a role in AML M7. Secretion of large amounts of this cytokine by the leukemic megakaryoblasts is believed to contribute to myelofibrosis, a condition of excess deposition of extracellular matrix by bone marrow fibroblasts that is frequently, but not exclusively, associated with this FAB type. 9, 10 Resistance to TGF-␤ has been reported for erythroid leukemia cells (AML M6) as well as for malignant cells of the lymphoid lineage. 8, [11] [12] [13] [14] The Smad proteins have been shown to be essential intracellular mediators of the growth inhibitory effects of TGF-␤. 15, 16 In response to TGF-␤ or the related factor activin, Smad2 is phosphorylated by the respective transmembrane serine threonine kinase receptor, associates with Smad4, and translocates to the nucleus, where it acts as a regulator of transcription. 17 Mitogenic cytokines can antagonize this pathway by interfering with nuclear accumulation of the Smad complex. 18 Smad signaling is disrupted in 50% of pancreatic carcinomas either by homozygous deletion of Smad4 or by LOH (loss of heterozygosity) and point mutation of the second allele. 3 In colorectal tumors, point mutations and LOH were found in approximately 10% of cases. 19, 20 However, Smad4 alterations are distinctly uncommon in gastric, lung, head and neck, breast, ovarian, prostate, bladder, hepatocellular, and renal cancers, neuroblastomas, melanomas, and osteosarcomas. [20] [21] [22] [23] [24] [25] [26] Absence of mutations in Smad4 has also been reported for hematological malignancies. 27 The mutation frequency of Smad2 has not been investigated as extensively to date. Sequence alterations in Smad2 have been found in 6% of colon carcinomas 28 and in 2/57 lung cancer specimens, 29 but were absent from 37 esophageal carcinoma 25 and 44 neuroblastoma samples. 24 We therefore used RT-PCR-SSCP and sequencing to search for mutations in Smad2 in bone marrow or peripheral blood samples from patients with ALL, AML M6, or AML M7, and in samples from various AML FAB types in which loss of one copy of chromosome 18 could be demonstrated by cytogenetic analysis. SSCP analysis focused on the MH1 and MH2 domains of Smad2, as these domains are conserved among the members of the Smad family, have been shown to be of functional importance, and all tumor mutations found so far are located in these regions.
Materials and methods

Cell lines
MUTZ-3 cells (AML M4; kindly provided by HG Drexler, DSMZ, Braunschweig, Germany) were grown at 37°C in 5% CO 2 in ␣-MEM supplemented with 20% fetal calf serum (FCS) and 400 U/ml GM-CSF. K562 (AML M6), Megal (AML M7), 156 (B-ALL; kindly provided by M Freund, University of Rostock, Rostock, Germany), and RiFo (established in our laboratory from a B-ALL patient) cells were grown at 37°C in 5% CO 2 in RPMI 1640 medium containing 10% FCS.
Patients
Bone marrow and peripheral blood was obtained from ALL and AML patients for diagnostic cytogenetic analysis over a time period of 10 years. Specimens were prepared for cytogenetic analysis and stored in methanol/acetic acid at −20°C for 1 month to several years. Fifteen ALL and 35 AML samples were analyzed in this study.
Cytogenetic analysis
Cell culturing, chromosome preparation and staining of chromosomes by Giemsa banding was performed as described previously. 30, 31 For chromosome painting, probes from Oncor (Gaithersburg, MD, USA) were used according to the manufacturer's protocol.
RNA extraction, reverse transcription, PCR, SSCP analysis
It has been shown previously that RNA prepared from fixed specimens is suitable for RT-PCR analysis. 32 Before RNA extraction, cells were washed once in ice-cold PBS to remove media or fixing solution. RNA was prepared using Trizol Reagent (Gibco BRL, Eggenstein, Germany) according to the manufacturer's instructions. cDNA synthesis was performed using random hexamer primers and M-MLV reverse transcriptase (Gibco BRL) in a 20 l reaction following the manufacturer's protocol.
1.5 l of this reaction served as template for each PCR reaction. Primers were as described by Eppert et al, 28 except that restriction sites for EcoRI and XbaI were included in the 5Ј and 3Ј primers, respectively, to facilitate cloning.
PCR conditions for primer pair 1 (amplifying the MH1 domain) were as follows: 60 mM Tris-HCl pH 8. For cell lines, one round of amplification using 35 cycles was sufficient; for patient material, another 25-35 cycles had to be carried out, which is most likely due to recovery of smaller quantities of RNA because of limited amounts of starting material. ␣-32 P dCTP was included only in the second set of cycles. cDNA from blood of healthy donors served as wildtype control. To test whether our SSCP conditions would indeed facilitate detection of mutations, plasmids containing mutated Smad2 were mixed with plasmid containing wildtype Smad2 in a 1:8 ratio, and further processed along with the cDNAs.
Approximately equal amounts of each PCR product were mixed with an equal volume of sample buffer (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol FF), heated for 10 min at 95°C, and loaded onto SSCP gels. For SSCP, two different conditions were used: 8% acrylamide, 0.2% bisacrylamide, 10% glycerol, 0.5× TBE, electrophoresed overnight at 2 W and room temperature; and 6% acrylamide, 0.15% bisacrylamide, 5% glycerol, 1× TBE, electrophoresed at 40 W for 2 h.
Sequencing
Sequencing reactions were either performed directly on PCR products or after subcloning into pUC18. In both cases, sequenase kits from USB (Cleveland, OH, USA) were used, following the manufacturer's protocol.
Results
Fifty primary leukemia samples as well as five cell lines were selected for RT-PCR-SSCP (reverse transcriptase polymerase chain reaction single-strand conformation polymorphism) analysis of the MH1 and MH2 domains of the Smad2 gene. Two of the cell lines were derived from lymphoid leukemia samples (156 and RiFo) and three were of myeloid origin (Mutz-3, Megal and K562). Of the primary tumor samples, 15 were from patients with ALL, and 35 from patients with AML (15 M6, seven M7, and 13 samples of other AML subtypes). The samples were selected from a large collection of material that had been analyzed cytogenetically by us previously (HR and CF), and samples with loss or rearrangement of one chromosome 18 were chosen preferentially. Thus, three of the lymphoid leukemia samples lacked one copy of chromosome 18 and three contained rearrangements involving chromosome 18. Two of the M6 samples as well as nine of the 13 samples from various FAB types showed loss of one chromosome 18 (Table 1 ). In some of the cases with complex karyotypic aberrations, complete absence of material from the missing chromosome 18 was demonstrated by chromosome painting.
RNA was prepared from cell lines or fixed bone marrow or blood samples from patients and reverse transcribed using random hexamer primers. Blood from healthy donors was used as a wild-type control. In order to ascertain that our SSCP conditions would indeed facilitate detection of mutations, plasmids containing mutated Smad2 were mixed with plasmid containing wild-type Smad2 in a 1:8 ratio and further processed in parallel with the cDNAs. Region 1, corresponding to the MH1 domain, and regions 2, 3 and 4, corresponding to the MH2 domain, were amplified in separate PCR reactions. PCR products were easily obtained from all cell lines, thus confirming that Smad2 is expressed in hematopoietic cells. 33 Amplification of patient specimens required additional PCR cycles, which most likely is due to smaller quantities of RNA isolated from limiting amounts of fixed material. However, RNA was of good quality, as primers for cytoskeletal actin readily amplified a product of the expected size from all samples, and bcr-abl could be amplified from two samples containing the Philadelphia chromosome t(9;22) (data not shown).
Smad2 PCR products were denatured and analyzed on nondenaturing acrylamide gels using two different sets of conditions (see Materials and methods). As exemplified in Figure  1 , additional bands were clearly apparent in the positive control samples, thus demonstrating that appropriate SSCP conditions had been chosen. However, no mutations could be detected in any of the samples from patients or cell lines. Sequence analysis of a minimum of five samples for each region confirmed our conclusion that Smad2 mutations are an infrequent event in acute leukemia.
Discussion
The recent cloning of Smad2 and Smad4, critical intracellular mediators of the growth inhibitory action of TGF-␤, has spurred a number of investigations about the possible inactivation of these genes in malignant diseases. In addition, considerable knowledge about the biochemical properties of these proteins has been gained, allowing an understanding of the mechanisms by which mutations found in cancer disrupt their function. In the presence of ligand, the TGF-␤ receptor 
Figure 1
Example of SSCP analysis. Region 1 of Smad2 (corresponding to the MH1 domain) was amplified from cDNA or control plasmids and concomitantly labelled with ␣-32 dCTP. Comparable amounts of each PCR product were denatured and electrophoresed on a non-denaturing polyacrylamide gel at 2 W overnight. Lane 1, wild-type Smad2 plasmid; lanes 2 and 9, Smad2(R133C) plasmid mixed with wild-type Smad2 plasmid in a 1:8 ratio; lanes 3-8, cDNA from patient samples.
serine threonine kinase phosphorylates Smad2, thus promoting its association with Smad4. 15 The resulting heterohexameric complex 34 translocates to the nucleus where it is presumed to act as a regulator of transcription. 35 Potential Smad target genes might include the TGF-␤ regulated cyclin-dependent kinase inhibitor p15. Cancer mutations were shown to interfere with Smad signaling either by abolishing ligand-dependent phosphorylation, 28 or by preventing oligomerization. 34, 36 In our analysis of 15 ALL and 35 AML samples we did not detect any point mutations in the MH1 and MH2 domains of Smad2. Despite certain technical limitations of the RT-PCR-SSCP technique, that is, the inability to detect splice site mutations, and the possibility of a low false negative rate, 37 our data, nevertheless, demonstrate that inactivation of Smad2 is an infrequent event in acute leukemia. This conclusion is in agreement with a recently published study by Ikezoe et al, 38 in which a different spectrum of hematological malignancies was analyzed for Smad2 mutations with essentially identical results. Similarly, no sequence alterations have been found in Smad4 in a panel of 162 leukemia and lymphoma cases, which included 21 AML, 24 childhood ALL, and 43 adult T cell leukemias, 27 or in Smad5, another Smad family member, in 27 cases with AML or MDS (myelodysplastic syndrome). 39, 40 It cannot be ruled out that inactivation of other Smad family members could contribute to the development or progression of leukemia. However, Riggins et al 41 screened 167 cell lines and xenografts from various types of solid tumors, including colorectal, breast, brain, lung and pancreatic cancers, for mutations in Smad1, 3, 5 and 6 without detecting any aberrations, thus making these genes less attractive as candidates for tumor suppressor genes.
Even though in some studies, including our own, RT-PCR has been used to generate products for SSCP analysis, this does not allow conclusions about the amount of transcript present. Therefore, the possibility remains that downregulation of transcription of Smad genes plays a role in reduced responsiveness to growth inhibitory signaling. Alternatively, the production or stability of Smad6 or Smad7, newly identified family members that antagonize TGF-␤ signaling, [42] [43] [44] could be upregulated.
However, even though not all possibilities have been inves-tigated yet, presently available data do not provide evidence for the involvement of Smad genes in leukemogenesis, thereby lending further support to the notion that the role of Smad genes as tumor suppressors might be restricted to a subset of cancers, and therefore be a tissue specific rather than a common mechanism of malignant transformation.
